Skip to main content
. Author manuscript; available in PMC: 2013 Apr 4.
Published in final edited form as: J Neurooncol. 2011 Sep 22;106(2):409–415. doi: 10.1007/s11060-011-0687-1

Table 2.

Survival estimates for all patients

Group Total Number of failed Median survival in months (95% CI) 6-month survival (95% CI) 12-month survival (95% CI) 24-month survival (95% CI) Logrank P-value
OS All 21 10 66 (20.7, 66) 85.7 (62, 95.2) 81 (56.9, 92.4) 66.7 (42.5, 82.5)
Grade I 8 2 66.0 (42, 66) 100 100 100 0.018
Grade II/III 13 8 20.9 (4.6, ∞) 76.9 (44.2, 91.9) 69.2 (37.3, 87.2) 46.2 (19.2, 69.6)
PFS All 21 20 7 (3.8, 9.2) 61.9 (38.1, 78.8) 23.8 (8.7, 43.1) 9.5 (1.6, 26.1)
Grade I 8 8 13.9 (4.1, 20.3) 87.5 (38.7, 98.1) 50 (15.2, 77.5) 12.5 (0.7, 42.3) 0.025
Grade II/III 13 12 5.3 (1.8, 7) 46.2 (19.2, 69.6) 7.7 (0.5, 29.2) 7.7 (0.5, 29.2)

OS overall survival, PFS progression-free survival, CI confidence interval